CA3103154A1 - Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof - Google Patents

Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof Download PDF

Info

Publication number
CA3103154A1
CA3103154A1 CA3103154A CA3103154A CA3103154A1 CA 3103154 A1 CA3103154 A1 CA 3103154A1 CA 3103154 A CA3103154 A CA 3103154A CA 3103154 A CA3103154 A CA 3103154A CA 3103154 A1 CA3103154 A1 CA 3103154A1
Authority
CA
Canada
Prior art keywords
macrophages
agent
monocytes
cells
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3103154A
Other languages
English (en)
French (fr)
Inventor
Tatiana I. NOVOBRANTSEVA
Igor Feldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verseau Therapeutics Inc
Original Assignee
Verseau Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseau Therapeutics Inc filed Critical Verseau Therapeutics Inc
Publication of CA3103154A1 publication Critical patent/CA3103154A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
CA3103154A 2018-06-29 2019-06-28 Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof Pending CA3103154A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862692463P 2018-06-29 2018-06-29
US62/692,463 2018-06-29
US201962810683P 2019-02-26 2019-02-26
US62/810,683 2019-02-26
US201962857199P 2019-06-04 2019-06-04
US62/857,199 2019-06-04
US201962867532P 2019-06-27 2019-06-27
US62/867,532 2019-06-27
PCT/US2019/039773 WO2020006385A2 (en) 2018-06-29 2019-06-28 Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof

Publications (1)

Publication Number Publication Date
CA3103154A1 true CA3103154A1 (en) 2020-01-02

Family

ID=68985243

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3103154A Pending CA3103154A1 (en) 2018-06-29 2019-06-28 Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof

Country Status (10)

Country Link
US (1) US20210189342A1 (https=)
EP (1) EP3813881A4 (https=)
JP (1) JP2021529753A (https=)
KR (1) KR20210040948A (https=)
CN (1) CN113164589A (https=)
AU (1) AU2019293600A1 (https=)
BR (1) BR112020026386A2 (https=)
CA (1) CA3103154A1 (https=)
TW (1) TW202023629A (https=)
WO (1) WO2020006385A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115739182A (zh) * 2022-11-17 2023-03-07 合肥机数量子科技有限公司 含单分散铁原子的过氧化物模拟酶及其制备方法和用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3866818B1 (en) * 2018-10-19 2025-07-23 Regenics AS Use of fish egg cellular extractt for wound healing
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
CA3141334A1 (en) 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
KR20220042128A (ko) * 2019-06-27 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도
CA3142838A1 (en) * 2019-06-27 2020-12-30 Verseau Therapeutics, Inc. Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US11987612B2 (en) 2019-11-04 2024-05-21 Alector Llc Siglec-9 ECD fusion molecules
JP2023508498A (ja) * 2019-12-30 2023-03-02 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション １型糖尿病を処置するためのマクロファージの膵臓内ｍ２極性化
WO2021154709A1 (en) * 2020-01-28 2021-08-05 Nanotomer, Inc. Clathrin-chimeric antibody receptor constructs for immune cell activation therapy in vivo
US11642629B2 (en) * 2020-03-20 2023-05-09 Saudi Arabian Oil Company Multi-layer composite gas separation membranes, methods for preparation, and use
CN115667544A (zh) * 2020-03-27 2023-01-31 无界生物公司 鉴定染色体外dna特征的方法
JP7560893B2 (ja) 2020-04-20 2024-10-03 デュオジェニック ステムセルズ コーポレーション 修飾マクロファージ、組成物およびその使用
WO2021263115A1 (en) * 2020-06-26 2021-12-30 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment
CN112837306B (zh) * 2021-02-20 2022-11-22 薛竟宜 基于深度学习和中智理论的冠状动脉病变功能学定量方法
CN113884682B (zh) * 2021-04-30 2023-07-21 中国医学科学院血液病医院(中国医学科学院血液学研究所) 检测巨核细胞或血小板表面标志分子的产品在制备检测感染的产品中的用途
WO2023004235A1 (en) * 2021-07-23 2023-01-26 University Of Florida Research Foundation, Incorporated Controlling pro-inflammatory macrophage phenotype through biofunctional hydrogel design
CN113897397B (zh) * 2021-09-30 2024-04-02 中南大学 一种基于DNAzyme调控基因编辑的方法
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
CN113913507A (zh) * 2021-10-29 2022-01-11 温州医科大学附属第一医院 Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用
CN114214237B (zh) * 2021-12-23 2023-06-16 南京大学 一种洗脱细胞表面吸附纳米颗粒的方法
CN115029473B (zh) * 2022-06-21 2024-06-18 湖北省药品监督检验研究院 一种基于mlpa技术对中药材桃仁与苦杏仁进行鉴别的方法
WO2024189098A1 (en) * 2023-03-13 2024-09-19 Iomx Therapeutics Ag Platform technology for the identification of modulators of immune effector cell function
CN116403649A (zh) * 2023-03-17 2023-07-07 中山大学附属第六医院 一种igsf6基因在免疫治疗治疗系统中的应用
AU2024237943A1 (en) * 2023-03-20 2025-10-09 The Regents Of The University Of California Methods and materials for treating cancer
CN117159495A (zh) * 2023-08-16 2023-12-05 北京大学 脂质纳米颗粒及其应用
TWI873056B (zh) * 2024-07-01 2025-02-11 國立成功大學 採用影像分割技術的胃內視鏡影像分析方法與電腦系統

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972703A (zh) * 2004-03-30 2007-05-30 丹麦皇家兽医和农业学院 通过阻断和检测蛋白酶抑制剂改进癌症的治疗和癌症治疗效率的预测
WO2009140623A2 (en) * 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US9139652B2 (en) * 2011-10-21 2015-09-22 Transgene Sa Method for increasing M1 macrophages in a patient
WO2015077401A1 (en) * 2013-11-20 2015-05-28 Drexel University Compositions and methods for macrophage conversion
US20170306042A1 (en) * 2014-08-29 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
GB201611535D0 (en) * 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
EP3568159A4 (en) * 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115739182A (zh) * 2022-11-17 2023-03-07 合肥机数量子科技有限公司 含单分散铁原子的过氧化物模拟酶及其制备方法和用途
CN115739182B (zh) * 2022-11-17 2024-01-16 合肥机数量子科技有限公司 含单分散铁原子的过氧化物模拟酶及其制备方法和用途

Also Published As

Publication number Publication date
TW202023629A (zh) 2020-07-01
US20210189342A1 (en) 2021-06-24
EP3813881A2 (en) 2021-05-05
WO2020006385A2 (en) 2020-01-02
EP3813881A4 (en) 2022-09-14
WO2020006385A3 (en) 2020-02-13
JP2021529753A (ja) 2021-11-04
BR112020026386A2 (pt) 2021-03-30
CN113164589A (zh) 2021-07-23
AU2019293600A1 (en) 2021-01-14
KR20210040948A (ko) 2021-04-14

Similar Documents

Publication Publication Date Title
CA3103154A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
KR102754524B1 (ko) 유방암 치료를 위한 진단 및 치료 방법들
KR102712656B1 (ko) Hsd17b13 변종 및 이것의 용도
CN109072237B (zh) 降低tau表达的组合物和方法
KR102301464B1 (ko) 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
KR102362647B1 (ko) 전반적으로 활성화된 단핵구를 수득하는 방법
US20190300967A1 (en) Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
KR20150122639A (ko) 면역억제성 수지상 세포를 얻는 방법
KR20200043549A (ko) 면역자극성 수지상 세포를 얻는 방법
CN115209923A (zh) 治疗肝病的组合物和方法
CA2518101A1 (en) Compositions and methods for the treatment of systemic lupus erythematosis
WO2006022628A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
WO2003014340A2 (en) Human histone deacetylase-related gene and protein hdac10
KR20180134896A (ko) 결장직장암 분류를 위한 마커 유전자, 결장직장암의 예후를 위한 림프노드 전이를 판단하는 방법 및 이를 위한 키트
WO2006022633A1 (en) Methods for identifying a risk of type ii diabetes and treatments thereof
KR20130087585A (ko) 저도 염증을 검출하는 방법
CN101190944A (zh) 人类新细胞因子及其用途
AU2026202687A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
RU2777570C2 (ru) Композиции и способы для снижения экспрессии tau
HK40057217A (en) Diagnostic and therapeutic methods for the treatment of breast cancer
JP2006166703A (ja) 軟骨分化制御遺伝子
HK40057217B (zh) 用於治疗乳腺癌的诊断和治疗方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240702

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241226

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241226

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20250627

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250627

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250702

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251126

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251217

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260219